Neoadjuvant camrelizumab plus chemotherapy improves pathologic complete response in stage IIIA and B NSCLC
Positive results from a phase II trial adds weight to the value of immunotherapy as neoadjuvant treatment for resectable NSCLC
Back to basics: do we need more immuno-oncology in the core curriculum?
Due to the current widespread use of immunotherapies and their increasing complexities, further immune-oncology education is needed in medical schools and beyond
Nina Bhardwaj receives the ESMO Immuno-Oncology Award 2022
According to the 2022 awardee, the future of immuno-oncology lies in the modulation of the tumour microenvironment and cancer vaccines
Is there still a future for cancer vaccines?
Despite generally disappointing clinical trial results, technological innovations mean that realising the potential for cancer vaccines could be just around the corner
Is combining radiotherapy and immunotherapy a viable treatment option?
Conflicting clinical results on the benefits of combined radiotherapy and immunotherapy may derive from differences in treatment sequencing
Benefits of immunotherapy in hepatocellular carcinoma are confirmed in Asian subpopulations
New subpopulation analyses from three international phase III trials confirm efficacy of immune checkpoint inhibitors across geographical areas
Nivolumab plus chemotherapy does not improve PFS in EGFR-mutated NSCLC
CheckMate 722 trial fails to meet its primary endpoint in patients with cancer progressing on one or two prior lines of EGFR tyrosine-kinase inhibitors
Hepatocellular carcinoma: apatinib after transarterial chemoembolisation prolongs PFS in a Chinese population
Positive results in intermediate and advanced disease come after the failure of global trials investigating the combination of TACE with targeted agents
National cancer registries in Asia – is Big Data the way to go?
Integrated, comprehensive databases may help to close the gap in cancer care between high- and low-/lower-middle-income countries
New PAGAs on endometrial cancer and metastatic breast cancer presented in Singapore
Differences in cancer population, local expertise, availability of and accessibility to treatments are incorporated into two new Pan-Asian adaptations (PAGA) of the ESMO Clinical Practice Guidelines